ClinicalTrials.gg
CompletedNCT00262301Updated Oct 2, 2012Results posted

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

A Phase 3 interventional study of recombinant human C1 inhibitor and Placebo in Hereditary Angioedema, Angioneurotic Edema and Genetic Disorders, sponsored by Pharming Technologies B.V.. Completed at 2 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-10-02.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. Complement C1 Inhibitor Protein · Angioedemas, Hereditary.

Enrollment
6th of 17
75 · median 32
Started
2004
the only one that year
Phase 3
8 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
4 of 17
Pharming Technologies B.V.

Among the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary, this one is the 6th largest by enrollment, is the only one that started in 2004, is one of 8 in phase 3, and was the 3rd registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About Complement C1 Inhibitor Protein

Complement C1 Inhibitor Protein: first FDA approval 2014 (Ruconest), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Complement C1 Inhibitor Protein in Angioedemas, Hereditary as a file.
02

Study summary

Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some cases, life-threatening. "HAE" is caused by mutations in the "C1INH" gene that leads to a decrease in the blood level of functional "C1INH". This multi-center study was designed to assess the safety and tolerability, efficacy and pharmacodynamics/ pharmacokinetics of recombinant human C1 inhibitor ("rhC1INH") in the treatment of acute hereditary angioedema attacks.

Read the detailed description

A prospectively planned interim analysis will be performed on the double-blind data.

03

Conditions studied

  • Hereditary Angioedema
  • Angioneurotic Edema
  • Genetic Disorders
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clear clinical and laboratory diagnosis of HAE
  • Baseline plasma level of functional C1INH of less than 50% of normal
  • Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack

Exclusion criteria

Exclusion Criteria:

  • Acquired angioedema
  • Pregnancy or breastfeeding
  • Participation in another clinical study within prior 3 months
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    100 IU/kg "rhC1INH"

    100 IU/kg recombinant human C1 inhibitor

    Drug: recombinant human C1 inhibitor

  • Placebo comparator
    Saline

    Saline solution

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Beginning of Relief of Symptoms

    The time to beginning of relief of symptoms has been assessed by using a patient-reported visual analogue scale ("VAS") ranging from 0 mm (no symptoms at all) to 100 mm (extremely disabling). Time to beginning of relief of symptoms at the location that showed first "VAS" score decrease of at least 20 mm from baseline score (t= 0 min) to the next assessment time-point). Assessment time-points were taken on pre-scheduled time-points after drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to beginning of relief has been calculated as median time, by using the exact time-points on which each assessment was performed.

    Time frame: up to 48 hours after study drug administration

Secondary outcomes

  1. Time to Minimal Symptoms

    the time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale ("VAS") score. Symptoms were said to be minimal when the "VAS" score at all locations was below 20 mm. Assessment time-points were: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to minimal symptoms has been calculated by using the exact time-points on which each assessment was performed.

    Time frame: up to 48 hours after study drug administration

07

Results

Posted Aug 30, 2012

Participant flow

During the double-blind phase of the study, patients were randomized once to receive 100 IU/kg "rhC1INH" or Saline in a ratio of 1:1. After conclusion of the double-blind phase, patients with subsequent eligible attacks could be treated with open-label 1 vial (2100 IU) of "rhC1INH".

Double-blind Phase
Participant flow — Double-blind Phase
Milestone100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"
Started16160
Completed15150
Not completed110
Withdrew: Lost to follow-up100
Withdrew: Worsening of "hae" symptoms010
Open-label Phase
Participant flow — Open-label Phase
Milestone100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"
Started0057
Completed0057
Not completed000

Outcome measures

PrimaryTime to Beginning of Relief of Symptoms

The time to beginning of relief of symptoms has been assessed by using a patient-reported visual analogue scale ("VAS") ranging from 0 mm (no symptoms at all) to 100 mm (extremely disabling). Time to beginning of relief of symptoms at the location that showed first "VAS" score decrease of at least 20 mm from baseline score (t= 0 min) to the next assessment time-point). Assessment time-points were taken on pre-scheduled time-points after drug administration: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to beginning of relief has been calculated as median time, by using the exact time-points on which each assessment was performed.

Time frame:
up to 48 hours after study drug administration
Reported as:
Median · minutes
Time to Beginning of Relief of Symptoms
minutes100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"
Time to Beginning of Relief of Symptoms62 (15 to 1470)508 (15 to 2880)61 (15 to 1455)
Statistical analysis
  • 100 IU/kg "rhC1INH" vs Saline · Log Rank · p = 0.003
SecondaryTime to Minimal Symptoms

the time to minimal symptoms was the time to minimal symptoms for an attack, assessed using the Visual Analogue Scale ("VAS") score. Symptoms were said to be minimal when the "VAS" score at all locations was below 20 mm. Assessment time-points were: baseline (0 minutes), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 48 hours. Time to minimal symptoms has been calculated by using the exact time-points on which each assessment was performed.

Time frame:
up to 48 hours after study drug administration
Reported as:
Median · minutes
Time to Minimal Symptoms
minutes100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"
Time to Minimal Symptoms480 (15 to 2400)1440 (31 to 2885)241 (15 to 4333)
Statistical analysis
  • 100 IU/kg "rhC1INH" vs Saline · Log Rank · p = 0.005

Adverse events

Collected over Treatment-Emergent-Adverse-Events ("TEAEs") were defined as events with start from onset of study drug administration. Serious Adverse events and Adverse events for each arm with onset dates within 7 days of study drug administration have been listed.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 IU/kg "rhC1INH"—0/16 (0%)2/16 (12.5%)
Saline—2/16 (12.5%)5/16 (31.3%)
1 Vial (2100 IU) "rhC1INH"—0/57 (0%)6/57 (10.5%)
Most frequent serious events
Most frequent serious events
Event100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"
Prostate examinationInvestigations0/161/160/57
Biliary colicHepatobiliary disorders0/161/160/57
Most frequent other events
Most frequent other events
Event100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"
headacheNervous system disorders1/162/163/57
painGeneral disorders0/162/160/57
menstrual disorderReproductive system and breast disorders1/160/160/57
scrotal swellingReproductive system and breast disorders1/160/160/57
pain in extremityMusculoskeletal and connective tissue disorders0/161/160/57
hypotensionVascular disorders0/161/160/57
nauseaGastrointestinal disorders0/160/163/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"Total
<=18 years11911
Between 18 and 65 years13123358
>=65 years2316
Sex: Female, Male
Sex: Female, Male(Participants)100 IU/kg "rhC1INH"Saline1 Vial (2100 IU) "rhC1INH"Total
Female892845
Male871530
08

Study locations

2 sites
  • For information on sites, please contact Pharming Medical Affairs Deparment
    Leiden, 2300 AL, Netherlands
  • Emergency County Hospital, Internal Medicin Clinica, Allergology-Immunology Department
    Tirgu Mures, 541103, Romania
09

References and documents

Publications

  • Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010 Oct;126(4):821-827.e14. doi: 10.1016/j.jaci.2010.07.021. PubMed 20920772 ↗
  • Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M, Triggiani M, Montinaro V, Cillari E, Realdi G, Cancian M, Visscher S, Zanichelli A, Relan A, Cicardi M. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy. 2012 Jun;42(6):929-35. doi: 10.1111/j.1365-2222.2012.03984.x. PubMed 22909164 ↗
  • Bernstein JA, Relan A, Harper JR, Riedl M. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2017 Apr;118(4):452-455. doi: 10.1016/j.anai.2017.01.029. Epub 2017 Mar 9. PubMed 28284978 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Jul 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2005
First posted
Dec 6, 2005
Start
Jun 2004
Primary completionActual
Jul 2009
CompletionActual
Oct 2009
Results first posted
Aug 30, 2012
Last update
Oct 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00262301
Responsible party
Sponsor
First posted
Dec 6, 2005
Start date
Jun 2004
Primary completion
Jul 2009
Completion
Oct 2009
Results posted
Aug 30, 2012
Last update
Oct 2, 2012

Study contacts

Jan Nuijens, MD, PhD
study chair · Pharming Group N.V.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Complement C1 Inhibitor Protein · Conestat alfa · C1 esterase inhibitor (human)

Start the discussion